Purdue inks multibillion-dollar opioid deal with thousands of local governments, more than 20 states: reports

OxyContin
Purdue has inked a "global" opioid settlement worth billions of dollars, according to reports. (PureRadiancePhoto/Shutterstock)

Purdue Pharma has entered the first major opioid settlement. The company, whose OxyContin played a role in the opioid epidemic, plans to file for bankruptcy imminently and restructure under an agreement with 23 states and nearly 2,300 cities, counties and tribes, according to The New York Times.  

Under the deal, Purdue’s founding family—the Sacklers—will pay plaintiffs $3 billion over seven years. Some state attorneys general had wanted them to pay $4.5 billion upfront, but the family refused, the newspaper reports.

Purdue will restructure under the agreement and keep selling OxyContin, with proceeds going back to plaintiffs to help remedy the nationwide opioid and addiction epidemic. The Washington Post pegged the total deal value at between $10 billion and $12 billion.  

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

The company and Sackler family won’t admit wrongdoing as part of the deal, according to reports. Even after the Sacklers pay the $3 billion, they'll get to keep billions in wealth. In 2016, Forbes estimated their net worth to be $13 billion. 

RELATED: Purdue offers up to $12B in opioid talks, reports say. Will that be enough? 

The settlement follows Purdue’s $270 million deal to resolve a lawsuit brought by Oklahoma. Wednesday’s agreement is the first “global” opioid settlement, according to the NYT, but it isn’t clear whether it’ll absolve the company or family members from all existing and future claims, such as those from states that didn’t sign on. 

Connecticut, New York and Massachusetts are among the states that haven’t joined the agreement, the NYT reports. Connecticut’s attorney general, William Tong, told the newspaper the state’s position “remains firm and unchanged and nothing for us has changed today.” 

“I cannot predict whether Purdue will seek bankruptcy, but all I can say is we are ready to aggressively pursue this case wherever it goes—whether it is in the Connecticut courts or through bankruptcy,” the attorney general added, as quoted by the NYT. 

Details of the deal emerged after NBC News and Reuters reported late last month the company offered up to $12 billion through the same restructuring and bankruptcy approach. According to those reports, the family offered $3 billion to plaintiffs.   

RELATED: Purdue talks may have stalled with state attorneys general, but cities and counties are still at it: AP 

Some state attorneys general weren’t pleased with the terms, sources told the The Wall Street Journal. Talks with certain attorneys general reportedly reached an impasse over the weekend as lawyers representing local plaintiffs pressed on.  

Purdue and other drugmakers face thousands of lawsuits, grouped up in Cleveland, alleging that drugmakers oversold opioid benefits and downplayed the risks. More than 40 states have sued as well. The first trial is set for October, and some drugmakers have inked small settlements with two Ohio counties in a bid to sidestep the trial. 

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.